Metabolite analysis of *Mycobacterium* species under aerobic and hypoxic conditions reveals common metabolic traits

Margit Drapal[1], Paul R. Wheeler[2] and Paul D. Fraser[1*]

[1]School of Biological Sciences, Royal Holloway University of London, Egham, U.K.

[2]Tuberculosis Research Group, Veterinary Laboratories Agency Weybridge, New Haw, U.K.

*Correspondence: Tel.: 01784-443894, Fax.: 01784-4434326, E-mail: P.Fraser@rhul.ac.uk.

Number of words in abstract: 261

Number of words in main text: 4708

Abstract (250 words)

A metabolite profiling approach has been implemented to elucidate metabolic adaptation at set culture conditions in five Mycobacterium species with the potential to act as model organisms for Mycobacterium tuberculosis (Mtb). Analysis has been performed over designated growth phases and under representative environments (nutrient and oxygen depletion) experienced by Mtb during infection. The procedure was able to determine a range of metabolites (60 - 120 compounds) covering nucleotides, amino acids, organic acids, saccharides, fatty acids, glycerols, -esters, -phosphates and isoprenoids. Among these classes of compounds key biomarker metabolites were identified that can act as indicators of pathway/process activity. In numerous cases, common metabolite traits were observed for all five species across the experimental conditions. Amino acid content, especially glutamic acid, highlighted the different properties between the fast- and slow-growing mycobacteria studied. The greatest similarities in metabolite composition between fast- and slow-growing mycobacteria were apparent under hypoxic conditions. A comparison to previously reported transcriptomic data revealed a strong correlation between changes in transcription and metabolite content. Collectively, these data validate the changes in the transcription at the metabolite level, suggesting transcription exists as one of the predominant modes of cellular regulation in Mycobacterium. Whilst, sectors with restricted correlation between metabolites and transcription (e.g. hypoxic cultivation) warrant further study to elucidate and exploit post-transcriptional modes of regulation. The strong correlation between the laboratory conditions used and data derived from in vivo conditions, indicates that the approach applied is a valuable addition to our understanding of cell regulation in these Mycobacterium species.

Introduction

The genus *Mycobacterium* contains a variety of species with different phenotypes (e.g. fast- and slow-growers, chromogens, pathogens and saprophytes) and hence, provides a range of suitable model organisms for Mtb. The suitability of *Mycobacterium* species as model organisms has been extensively discussed highlighting differences/similarities in growth rate, cell envelope chemistry, pathogenicity/biosafety and their phylogenetic relationship compared to Mtb (e.g. Barry, 2001). For the purpose of this study, two fast-growing (*M. smegmatis* and *M. phlei*) and three slow-growing (*M. bovis* BCG, *M. avium* and *M. intracellulare*) mycobacteria were chosen to represent a diverse range of *Mycobacterium* species. These mycobacteria were analysed at set growth stages to show adaptation processes upon the induction of abiotic stresses (e.g. nutrient and oxygen limitation through natural depletion of given resources) which are comparable to the microenvironment experienced by Mtb. The metabolite levels monitored elucidated metabolic pathways common to the genus *Mycobacterium* (e.g. mycolic acid synthesis (Gago *et al.*, 2011)) and specific to certain phenotypes mentioned above (e.g. poly-glutamine synthesis in slow-growers (Harth and Horwitz, 1999)).

The culture conditions in the present study were based on published *in vitro* models (Wayne and Hayes, 1996) to represent typical environments experienced by Mtb under physiological conditions. The prevalent stress conditions experienced within the host, including infection stages of active replication in alveolar macrophages and dormancy within granulomas (Chao and Rubin, 2010), involve a gradual depletion of oxygen and nutrients (Russell *et al.*, 2010). To minimise environmental influences on the mycobacterial cells, they were cultivated in a standardised volume of nutrient rich medium with no additionally supplementation over the duration of the experiments creating a natural depletion of nutrients over the period of batch cultivation. The three culture conditions investigated included growth from lag to stationary phase (Phase I) and growth from logarithmic (log) phase for 28d under aerated (Phase II) or hypoxic (Phase III) conditions. To capture the changes in metabolites occurring under these conditions a quantitative metabolite profiling approach was used (Drapal *et al.*, 2014). The resulting changes at the metabolite level were compared with previous published transcriptomic and proteomic data (e.g. (Betts *et al.*, 2002; Hampshire *et al.*, 2004)) for a better understanding of cellular regulation in *Mycobacterium* and its changing chemotype with environmental adaptation. Collectively, these data will enable an assessment of how representative the laboratory conditions used are compared to real life scenarios.

Material and Methods

Bacteria

M. smegmatis (National Collection of Type Cultures (NCTC) 8159, Public Health England,)), *M. phlei* (NCTC 8151), *M. bovis* BCG (Pasteur strain, from AHVLA Collection, Weybridge, UK), *M. avium* (serotype 8, private collection) and *M. intracellulare* (serotype 7, private collection) were cultivated and prepared as a starting culture as published previously (Drapal *et al.*, 2014). For the following culture conditions five replicates per species were grown in parallel.

For Phase I cultivation, fresh Middlebrook 7H9 supplemented with 10% OADC (oxalic acid,-albumin-dextrose-catalase) and 0.4% Tween 80 was inoculated with the starting culture until an initial optical density at 600nm (OD) of 0.1 or 0.05, for fast- and slow-growing mycobacteria respectively, was reached. The cultures (1.5 times the total volume sampled) were then incubated shaking (180 rpm, 37°C) under aerated conditions in vent-cap flasks.

For the other two culture conditions, fresh medium (1.5 times the total volume sampled) was inoculated as described for Phase I and incubated shaking (180 rpm, 37°C) under constant aeration in vent-cap flasks. After 16h (*M. smegmatis*), 1d (*M. phlei*) or 7d (*M. bovis* BCG, *M. avium*, *M. intracellulare*) an aliquot (8 ml) of the inoculated medium was sampled representing the induction point of the two different oxygen conditions. The aerated, shaking condition was maintained for Phase II cultivation and samples (8 ml) were taken at 1d, 2d and 28d after induction for all mycobacteria. For the hypoxic cultivation (Phase III), the cultures were aliquoted (8 ml) at the induction point and all aliquots cultivated without stirring at 37°C until sampled for analysis. The depletion of oxygen in the hypoxic culture was visualised by discolouration of methylene blue (1.5 µg/ml cell culture). Aliquots of inoculated medium (8 ml) were sampled following the same time regime as described for Phase II.

Sampling and analysis of polar and non-polar metabolites

Aliquots of the cultures were quenched with isotonic 60% (v/v) methanol, centrifuged and the resulting cell pellet weighed. The cells were the extracted with a methanol/chloroform method followed by analysis with gas chromatography mass spectrometry (GC/MS) and high performance liquid chromatography (HPLC) as previously published (Drapal *et al.*, 2014). The metabolites of each sample were identified through a customized library (Drapal *et al.*, 2014). Variation in the number and type of metabolites identified occurred at each sampling point. The GC/MS results were normalised to the internal standard and weight of the cell pellet. The identified compounds within each culture condition were compared to the first time point taken. Statistically significant changes of metabolites were analysed with one-way ANOVA with Dunnett's post-test and were then plotted over a pathway diagram.

Identification of lipids and proteins of the secreted layer

After four days of induction of hypoxia, the secreted layer was carefully removed from the cell pellet and separately analysed for lipid and protein content. For the identification of lipids, the collected secreted layer was dissolved (1:2) in chloroform/methanol/water (10:10:3, v/v/v). The diluted sample was then mixed (1:1) with 2,5-dihydroxybenzoic acid matrix (5 mg/ml in acetonitrile with 0.1% (v/v) trifluoroacetic

113   acid) and placed on a 600 µm Anchor chip 384 format MALDI target plate (Bruker Daltonics) before
114   analysis with MALDI–TOF/TOF-MS as described previously (Jones *et al.*, 2013).

115   For the identification of proteins of the secreted layer, a previously published protocol (Robertson *et al.*,
116   2012; Mora *et al.*, 2013) was followed which included precipitation of proteins and separation by SDS-
117   PAGE followed by in-gel digestion of the four major protein bands and analysis with nano-LC/MS/MS.
118   The proteins were identified through the detected peptides as previously published (Nogueira *et al.*,
119   2013) with SwissProt protein database for taxonomy *M. tuberculosis* complex.

120

121   **Results**

122   **Growth properties under aerated and hypoxic cultivation**

123   The growth curves for all three culture conditions were measured by monitoring optical density (OD)
124   and colony forming units (cfu) (Supplementary File 1). Both these measurements over Phase I showed
125   the typical sigmoid shape for all five mycobacteria (Fig. 1). The culture condition Phase II was
126   characterised by an almost horizontal linear curve at at least 2d after log phase. Again all five
127   mycobacteria showed similar growth properties (Fig. 1). The OD data was consistent with the cfu
128   measurements and indicated a constant viable count of culturable cells which is associated with data
129   found for non-replicating persistence (NRP) 1 (Chao and Rubin, 2010; Shi *et al.*, 2010; Bacon *et al.*,
130   2014). The exception was *M. phlei* which showed a decline of growth from 1d to 2d after the log phase
131   followed by constant values until 28d suggesting a death phase before the switch to NRP (Bacon *et al.*,
132   2014). Interestingly, a resurgent increase of cfu values was detected at 28d (Phase II) only for *M.*
133   *smegmatis, M. avium* and *M. intracellulare* which indicated a reactivation of cells or a second log phase
134   of the remaining active cells. Phase III cultures, contrary to Phase II, showed an immediate stop of
135   replication at the first time point after induction of hypoxic conditions conferred by the removing of
136   agitation (Fig. 1). This was shown through constant values similar to the induction point (log phase)
137   measured until 28d and would indicate that the cells are capable of rapid detection/adaptation to the
138   change in oxygen concentration. This change in condition was monitored *in situ* by the reduction of
139   methylene blue in the medium. Discolouration arose four hours after induction, which was approximately
140   half the duration required for all cells to settle at the bottom of the culture tube and was the same for all
141   five mycobacteria. All samples retained the discolouration throughout Phase III.

142   The metabolite profile was measured at each set time point and compared to the first time point of the
143   culture condition for each *Mycobacterium* species separately. The resulting changes of metabolite
144   levels were calculated and their significance evaluated (Supplementary File 2). Key metabolites within
145   the data set were chosen to visualise changes of nucleotides, the nitrogen and sulphur pathways, TCA
146   cycle, glyoxylate shunt, the biosynthesis of fatty acids and complex lipids and thus describe the
147   metabolic state over the growth stages.

148   **Metabolite changes occurring at the logarithmic and stationary growth phases (Phase I)**

149   Overall ~70 compounds were detected throughout Phase I for four of the five mycobacteria tested. *M.*
150   *phlei* was the exception with 126 metabolites detected. The summarised Phase I data for all five
151   mycobacteria (Fig. 2) highlighted the differences in metabolite levels between the fast-growing and the
152   slow-growing *Mycobacterium* species. Interestingly, the slow-growers had decreased metabolite levels
153   predominantly, when compared to lag phase, which suggested that metabolites associated with primary
154   metabolism were not detectable or rapid utilisation occurred. The data on the fast-growers, *M. phlei* and
155   *M. smegmatis*, showed increased levels of polar metabolites suggesting accumulation of the latter. *M.*
156   *bovis* BCG, being one of the slow-growing mycobacteria, showed similar metabolite changes to *M.*
157   *avium* and *M. intracellulare* but differed from the latter two as more metabolites were detected in *M.*
158   *bovis* BCG including uracil, glycine, fatty acid precursors and intermediates of the TCA cycle.

159   The common nucleotide detected in *M. smegmatis, M. bovis* BCG and *M. phlei* was uracil and showed
160   increased levels from log phase onwards. *M. phlei* had the most nucleotides detected which showed
161   the same increasing trends as uracil (Supplementary File 2). No nucleotides were detected for *M. avium*
162   and *M. intracellulare* over Phase I which would be compliant with rapid utilisation.

163   Homocysteine, the key intermediate of the sulphur pathway, can be metabolised via cysteine to
164   mycothiol (Zeng *et al.*, 2013) or converted to methionine (Singhal *et al.*, 2013) leading to reduced levels
165   of the latter as detected throughout Phase I, in four out of five mycobacteria tested. *M. phlei* was the
166   only *Mycobacterium* species in this study for which no homocysteine but increased cysteine levels were
167   detected.

168   Glutamic acid, the preferred nitrogen assimilation product (Amon *et al.*, 2009), showed higher levels at
169   log compared to the stationary phase in *M. phlei* and *M. smegmatis. M. intracellulare* was the only slow-
170   growing species which showed up-regulation of glutamic acid at stationary phase. The other two slow-
171   growing species, *M. bovis* BCG and *M. avium*, had decreased levels of glutamic acid. Additionally, in
172   *M. bovis* BCG levels of proline were increased.

173   The only intermediate of the TCA cycle which was detected in all five mycobacteria studied throughout
174   Phase I was succinic acid. This intermediary metabolite connects the TCA cycle, glyoxylate shunt and
175   methylcitrate cycle, which are all involved in fatty acid synthesis and catabolism (Eoh and Rhee, 2013).
176   Succinic acid and odd-chain fatty acids were decreased in the three slow-growing mycobacteria studied.
177   In the case of *M. phlei* and *M. smegmatis,* levels of succinic acid showed no change or an increase at
178   log phase, respectively. For glyoxylate, the key intermediate of the glyoxylate shunt, the derivative
179   glycolate was detected by GC/MS, due to chemical structures created during derivatisation process.
180   Glycolate was down-regulated throughout Phase I in all mycobacteria studied, except *M. smegmatis* for
181   which no glyoxylate was detected. Additionally, malonic acid, the dicarboxylic acid of malonyl-CoA, was
182   detected and its levels increased at the stationary phase for *M. bovis* BCG and *M. smegmatis* and at
183   the log phase of *M. phlei.* The even-chain fatty acids, consecutive intermediates of malonyl-CoA and
184   precursors for biosynthesis of mycolic acids (Crellin *et al.*, 2013), were reduced in all five mycobacteria
185   studied throughout Phase I. Similarly, the content of glycerol, utilised for glycero- and phospholipid
186   biosynthesis (Crellin *et al.*, 2013), was decreased or at levels below the limit of detection. Besides
187   malonic acid, fatty acid precursors isoleucine, threonine, leucine and valine were detected with
188   increased levels for *M. bovis* BCG, *M. smegmatis* and *M. phlei*.

189   Saccharides associated with components of the cell wall (arabinose, galactose, inositol, mannose and
190   trehalose) showed different trends in all mycobacteria tested over Phase I. Arabinose, part of the
191   arabinogalactan, was only detected in *M. smegmatis* at stationary phase. Galactose, also part of the
192   arabinogalactan, was decreased in all mycobacteria except *M. phlei* which showed increased levels at
193   log and no change at the stationary phase. Contrary to this, inositol and mannose-6-phosphate, both
194   components of plasma membrane related lipids, were increased in all mycobacteria except *M. avium,*
195   which showed decreased levels throughout Phase I. Trehalose, the backbone of trehalose mono- and
196   dimycolates (TMM, TDM), showed the most differences in contents between the five mycobacteria
197   tested. It was increased throughout Phase I for *M. smegmatis*, at log phase for *M. phlei,* at stationary

198 phase for *M. intracellulare* and showed no change and decreased levels throughout in *M. avium* and
199 *M. bovis* BGC, respectively.
200 An essential metabolite for the electron transport chain is menaquinone (MK) 9, the major lipoquinone
201 in *Mycobacterium* species (Mathew *et al.*, 2010). It was detected with overall decreased contents
202 compared to lag phase in all mycobacteria studied and showed increasing levels between log and
203 stationary phase for all species except for *M. phlei*. The data for *M. phlei* showed further decrease of
204 MK9 from log to stationary phase and increased levels of β-carotene throughout Phase I. *M.*
205 *intracellulare,* the other chromogenic *Mycobacterium* species studied, produced only phytoene, a
206 colourless carotenoid which represent the first step in the C40 pathway, during Phase I. Metabolite
207 profiling features found over Phase I, such as even-chain fatty acid and glycerol metabolism and MK9
208 levels, highlighted similarities between the mycobacteria studied.
209

210 **Metabolic changes under elongated aerated cultivation (Phase II)**

211 In all five mycobacteria, more compounds were detected over Phase II compared to Phase I. *M. phlei*
212 had the most metabolite changes measured over Phase II which were mainly lower levels compared to
213 the initial time point of measurement (Fig. 3).
214 Nucleotide metabolism appeared to be active in all five mycobacteria as a variety of changes in
215 nucleotide constituents were detected throughout Phase II. Amino acid content was unchanged for *M.*
216 *avium* and *M. intracellulare* at 1d and 2d, respectively, and decreased for *M. phlei*. Contrary to this, *M.*
217 *smegmatis* and *M. bovis* BCG showed an increase in number and levels of amino acids especially at
218 2d of Phase II.
219

220 Even though the overall trends of amino acid levels differed between the five mycobacteria studied, the
221 amino acids involved in the sulphur and nitrogen pathways were similar between them.
222 Homocysteine/cysteine content showed no change overall and glutamic acid levels showed a
223 decreasing trend throughout Phase II after an initial increase for *M. smegmatis* and *M. intracellulare.*
224 Additionally, *M. phlei* had decreased levels of biochemically related consecutive intermediates of
225 glutamic acid (ornithine and citrulline), whereas *M. bovis* BCG and *M. smegmatis* showed increased
226 levels at 1d or 2d (proline and ornithine) (Supplementary File 2).
227 The glyoxylate shunt seemed activated after 1d for *M. smegmatis* and after 2d for BGC and *M. avium*
228 which was indicated by increased levels of glyoxylate and/or glycine. *M. intracellulare* showed
229 decreased levels of glyoxylate at 2d and no change of glycine. Whereas, *M. phlei* had decreased levels
230 of both glyoxylate and glycine throughout Phase II with a further decrease from 1d to 2d.
231 The metabolite profiling data of Phase II showed that trehalose and glycerol contents were related to
232 even chain fatty acid levels which are all precursors for the biosynthesis of TDM or triacylglyceride
233 (TAG). In *M. phlei,* fatty acids and trehalose were decreased, whereas in the three slow-growing species
234 no change was detected for both trehalose and fatty acids within the first two days of Phase II.
235 Furthermore, glycerol-3-phosphate was increased for *M. bovis* BCG and *M. intracellulare* and together

with glycerol-esters decreased in *M. avium* and *M. phlei.* Only *M. smegmatis* showed no change of fatty acids, an increase in trehalose and a decrease of glycerol-3-phosphate.

The chromogenic mycobacteria (*M. phlei* and *M. intracellulare*) and *M. smegmatis* had increased levels of isoprenoids throughout Phase II and increased levels of MK9 at 1d except for *M. phlei* which showed no change in MK9 levels. *M. avium* and *M. bovis* BCG showed no change of MK9 and an additional MK (MK8) was detected for *M. bovis* BCG.

Cultivation of mycobacteria tested over Phase II highlighted differences between the *Mycobacterium* species, especially for *M. phlei* which showed down-regulated metabolite levels throughout Phase II and even further decreases at 28d whereas the other mycobacteria showed a predominantly positive metabolic switch at the last time point. At 28d, *M. smegmatis* showed increased levels of the glyoxylate shunt, sulphur pathway and fatty acids and *M. bovis* BCG showed increased levels of the glyoxylate shunt, nucleotides and fatty acid precursors indicating activated energy metabolism and induced activity for cell replication. At the same time, *M. avium* and *M. intracellulare* showed a distinct metabolic activation of all pathways with mainly increased levels except for glycerol-esters which were decreased. For *M. smegmatis, M. avium* and *M. intracellulare* these metabolic changes at 28d were also reflected with increased cfu values as described earlier.

Effects of hypoxic culture conditions on metabolite levels (Phase III)

Over Phase III, mycobacterial cells were not agitated and became oxygen-depleted, a well-documented effect (Wayne and Sohaskey (2001). The measured changes of metabolites over Phase III were more similar between the five mycobacteria tested (Fig. 4) compared to the data described for Phase II. In general, fewer metabolites were detected in Phase III (~90) than Phase II (~110).
The number of nucleotides detected followed this trend with a decrease in amount and number or a general lack of nucleotides detected for *M. smegmatis, M. avium* and *M. intracellulare*, respectively. In *M. bovis* BCG uracil showed increased levels after 2d and in *M. phlei* the highest number of nucleotides was detected with increased levels of most nucleotides at 1d (Supplementary File 2).

No change of homocysteine levels was detected for *M. bovis* BCG throughout Phase III, for *M. intracellulare* after 1d and for *M. smegmatis* and *M. avium* until 28d. All three mycobacteria had increased levels of homocysteine at the other time points. As seen in Phase I and II, only cysteine was detected in *M. phlei* with decreased levels throughout Phase III.
A striking observation was the decrease of glutamic acid in all three slow-growers throughout Phase III whereas the fast-growing species showed increased levels. Only two biochemically related consecutive metabolites, proline and ornithine, were detected in *M. smegmatis* and *M. phlei,* respectively, with increased content at 1d.
The succinic acid levels varied for all five mycobacteria tested. *M. smegmatis* and *M. avium* showed decreased levels from 1d and 2d, respectively, in *M. bovis* BCG no change occurred and *M. phlei* and *M. intracellulare* showed increased followed by decreased levels of succinic acid at 1d and 2d, respectively. Similar to succinic acid, precursors for lipid and cell wall synthesis (glycerol, fatty acids

275 and saccharides) were expressed with different metabolite levels for all mycobacteria. *M. smegmatis*
276 and *M. avium* showed decreased levels of glyercol-3-phosphate whereas *M. phlei* and *M. intracellulare*
277 showed increased levels of glycerol-3-phosphate and -esters, respectively, at 1d followed by no change
278 from 2d onwards. *M. bovis* BCG showed an increase of glycerol, -phosphate and –esters and most fatty
279 acids at 2d with the exception of decreased levels of C18:0 throughout Phase III, a fatty acid favoured
280 for first or second position of TAG (Walker *et al.*, 1970). Arabinose was detected in *M. smegmatis* at 1d
281 and in *M. phlei* and *M. avium* at 28d. Galactose content was mainly unchanged over Phase III apart
282 from decrease throughout in *M. smegmatis* and increase at 1d in *M. phlei*. At 1d *M. phlei* also had an
283 increased content of mannose which was otherwise unchanged for the other four species. Inositol and
284 trehalose were detected with similar trends of levels over Phase III. For *M. smegmatis* they were
285 increased over the first two days and at 2d, respectively. In *M. avium* both saccharides were decreased
286 after 1d and 2d, respectively. Inositol and trehalose were unchanged in *M. bovis* BCG until 28d at which
287 point they were decreased. *M. intracellulare* also showed unchanged levels of inositol and an increase
288 at 28d whereas trehalose was increased until 2d and showed no change at 28d. In *M. phlei*, trehalose
289 and inositol were increased at 1d followed by no change of trehalose and decreased levels of inositol.
290 MK9 levels showed no change over Phase III for all mycobacteria tested and for *M. intracellulare* after
291 1d. For *M. bovis* BCG MK8 and MK9 were detected as described for Phase II. A smaller number of
292 carotenoids (less than half) was detected for *M. phlei* and *M. intracellulare* over Phase III compared to
293 Phase II. The carotenoids showed no change except for phytoene which was increased throughout
294 Phase III.
295 At 28d of Phase III a renewed change of metabolite levels were detected similar to Phase II but without
296 an increase in cfu number. *M. bovis* BCG and *M. smegmatis* showed activation of sulphur and energy
297 metabolism (e.g. glyoxylate shunt, fatty acid metabolism) and an increase of nucleotide levels
298 (Supplementary File 2). *M. smegmatis* and *M. intracellulare* had increased contents of almost all fatty
299 acids detected. Furthermore, *M. avium* and *M. intracellulare* showed activity for all metabolic pathways
300 as described for Phase II with the exception of increased levels of nucleotides for *M. avium*.
301
302 The most striking property of the hypoxic cultivation was a secreted lipid layer of only the two fast-
303 growing *Mycobacterium* species (Fig. 5a). Three to four days after induction of hypoxic conditions, a
304 translucent layer became visible right above the cell pellet and showed a clear separation from the
305 medium. The control tube, containing bacterial-free medium, showed no such occurrence, indicating
306 that the layer was a product of the bacteria. In the case of the chromogenic *M. phlei,* the extracellular
307 material was coloured yellow/orange throughout and showed a zone of denser colouration at the border
308 to the cell pellet. Analysis of carotenoids extracted from the secretion did not show any results as the
309 amount of carotenoids was below the level of detection due to the volume of secretion per tube (~50
310 µl/10 mg cell pellet). Thus, the concentration of carotenoids could be significant but the total amount of
311 extracellular material precludes adequate extractable amounts.
312 After collection, the secreted layer was analysed for metabolite and protein composition. The analysis
313 with MALDI showed two series of peaks from 525 to 917 m/z and 1005 to 2035 m/z (Fig. 5b). The
314 fingerprint of the molecular ion peaks was typical for MALDI spectra of TAG as seen through

comparison with TAG spectra of *M. brumae* (Rafidinarivo *et al.*, 2009). The MALDI data suggested that TAG was the main compound of the secretion as no other spectra were detected in the sample. The two series of peaks in the TAG spectrum of *M. smegmatis* further indicated two different types of TAGs due to a combination of fatty and mycolic acids with different chain length as described for *M. brumae* (Rafidinarivo *et al.*, 2009).

For the protein analysis, proteins were extracted from the secreted layer and separated by SDS-PAGE. The same pattern of protein bands was seen for both fast-growing mycobacteria. The two major protein bands of both species were identified as a putative diacylglycerol O-acyltransferase (DGAT, ~63 kDa) from *Mycobacterium* and acyl-CoA acetyltransferase (ACAT, ~40 kDa). Furthermore, a match for the early secreted antigen target (ESAT)-6-like protein EsxB (~11kDa) was found.

Discussion

The metabolome, as the end product of gene expression and protein regulation (Harrigan and Goodacre, 2003; Boshoff and Lun, 2010), can be used to give a mechanistic insight into adaptation processes of an organism. An example in the present study is increasing levels of uracil detected through all culture conditions as part of DNA repair of G+C rich bacteria in macrophage infections (Venkatesh *et al.*, 2003; Cossu *et al.*, 2012). Difficulties of metabolite profiling methods, including the quick metabolic turn-over and leakage during sampling, were minimised in the approach used (Drapal *et al.*, 2014) and results reveal snapshots of the intracellular metabolism. Furthermore, the comparison of the metabolic data with transcriptional and translational data elucidates the principal mode of cellular regulation during adaptation to a stress condition.

The identified common properties of all mycobacteria specific to a culture condition (Fig. 6) were consistent with transcriptional and translational data published (e.g. during macrophage infection (Sassetti and Rubin, 2003)). For Phase I this included an active nucleotide and amino acid metabolism (Wang *et al.*, 2005) which ceased with cell replication over Phase III as reported under *in vivo* and *in vitro* conditions (Wayne and Sohaskey, 2001; Betts *et al.*, 2002). Additionally, changes in homocysteine levels as precursor for cell wall maintenance (Dhiman *et al.*, 2009) and for protein and nucleotide synthesis (Singhal *et al.*, 2013) were detected. MK9 and isoprenoids, both involved in the electron transport chain, seemed to play an essential interconnected role over all three conditions tested (Lee *et al.*, 2008; Dhiman *et al.*, 2009). Another important and already well known compound class for mycobacteria are lipids which act as a barrier to the environment (e.g. TDM) (Archuleta *et al.*, 2005) and as carbon/energy storage (e.g. TAG) (Crellin *et al.*, 2013). Their precursor metabolites detected included fatty acids, monosaccharides and glycerol derivatives. All of these metabolites displayed an active metabolism during replication cycles for plasma membrane and cell wall (Sassetti *et al.*, 2003; Crellin *et al.*, 2013) as well as part of the adaptation to environmental changes (Archuleta *et al.*, 2005) and the transition to the dormant state in Mtb as reported in mycobacterial infections (Stehr *et al.*, 2013).

One typical mycobacterial feature is the redirection of the carbon flow under reduced oxygen conditions which results in a switch of the TCA cycle to the glyoxylate shunt (Sassetti and Rubin, 2003; Eoh and Rhee, 2013). Succinic acid and glyoxylate, both products of the isocitrate lyase in the glyoxylate shunt (Eoh and Rhee, 2013), were detected in this study. The detection of both of those metabolites over Phase I suggested that the glyoxylate shunt was already activated during active replication contrary to published literature (e.g. Wayne and Sohaskey, 2001; Chao and Rubin, 2010). Levels of glyoxylate and related metabolites indicated a far less active glyoxylate shunt over Phase II than that described for a transcriptomic study following progressive nutrient depletion similar to the conditions in the present study (Hampshire *et al.*, 2004).

The main metabolic changes, which showed distinct differences between fast- and slow-growing mycobacteria, were glutamic acid levels and sequestration of TAG over Phase III. Increased levels of glutamic acid in the fast-growing species over Phase I were coherent with nitrogen assimilation under nitrogen excess in the medium (Amon *et al.*, 2009) and suggests that fast-growing species can sense upcoming limitation in the surrounding medium and adapt accordingly (Smeulders *et al.*, 1999). Contrary to this, glutamic acid levels over Phase I in the slow-growing species were consistent with utilisation of the latter for nucleotide and protein synthesis and transcriptional data for optimal growth

368 (Sassetti *et al.*, 2003). Over Phase III the lack of nucleotides in combination with decreased levels of
369 glutamic acid in slow-growing species suggested secretion of glutamic acid into the extracellular
370 environment. Pathogenic mycobacteria (e.g. *M. bovis* and *M. tuberculosis*) are known to release
371 glutamine synthetase during infection and synthesise poly-L-glutamate/glutamine as an extracellular
372 carbon and nitrogen storage (Harth and Horwitz, 1999). The intracellular accumulation of glutamic acid
373 for non-pathogenic mycobacteria (e.g. *M. phlei* and *M. smegmatis*) supports the hypothesis that
374 glutamic acid secretion is a trait of pathogenic mycobacteria.

375 For fast-growing species a release of TAG into the medium was observed a few days after Phase III
376 induction (Fig. 5). Lipid body formation with TAG is a common property of mycobacteria during the
377 hypoxic phase of the infection (e.g. Garton *et al.*, 2002; Low *et al.*, 2009) and *M. smegmatis* is known
378 to constantly releasing fatty acids or TAG into the medium (Selishcheva *et al.*, 2012). The proteins
379 detected in the secreted layer suggest simultaneous synthesis of TAG by DGAT similar to mycobacterial
380 infections (Stehr *et al.*, 2013) and β-oxidation of fatty acids by ACAT for butyryl-CoA and acetyl-CoA
381 synthesis (Kanehisa *et al.*, 2006). DGAT was detected in higher amounts than ACAT, resulting in more
382 TAG synthesis compared to β-oxidation and consequently the visible TAG layer. Saprophytic
383 mycobacteria usually cannot gain access to lipids originated from a host such as pathogenic
384 mycobacteria (Russell *et al.*, 2010). In the present study, oleic acid was available in the medium in its
385 free form and through hydrolysis of Tween 80. Hence, the production and secretion of TAG with oleic
386 acid might be the adaptation process of choice for non-pathogenic mycobacteria to create an
387 environment similar to foamy macrophages during infection with Mtb (Stehr *et al.*, 2013) and secure
388 storage of extracellular signalling metabolites (oleic acid) for resuscitation (Selishcheva *et al.*, 2012).
389 Similar metabolic changes related to TAG synthesis were detected over Phase II and highlight that TAG
390 synthesis and secretion might be a reaction to stressful conditions including nutrients and/or oxygen
391 depletion, leading to a NRP state (Wayne and Sohaskey, 2001). The metabolic changes related to
392 phenotypes suggests a possible genetic variation between pathogenic and non-pathogenic
393 mycobacteria due to necessities presented by their respective ecological niches.

394 In the present study a renewed increase in metabolic activity and growth rate was detected at 28d of
395 Phase II and III cultivation for all mycobacteria tested. The metabolic activities correlated with gene
396 expression for optimal growth over Phase I (Sassetti *et al.*, 2003), which indicates the presence of active
397 and "dormant" cells in the culture. This supports reports of heterogeneous culture in *in vivo* and *in vitro*
398 studies and suggested that this phenomenon is a mycobacterial trait and might provide new insight into
399 NRP cultures (Smeulders *et al.*, 1999; Chao and Rubin, 2010).

400 Despite the metabolic differences of non-pathogenic and pathogenic mycobacteria, a comparison of
401 their metabolic features provided valuable insight to *in vivo* studies as metabolic reactions detected
402 were consistent with results described for mycobacteria under macrophage infection. The present study
403 revealed that all *Mycobacterium* species maintain an active turn-over of metabolites involved in
404 transcription, translation and other general cellular processes through all three culture conditions. The
405 comparison with published literature highlighted that metabolic changes over a gradually occurring
406 nutrient depletion (Phase I and II) seemed to be more influenced by transcriptional and translational
407 processes, whereas cells experiencing a sudden oxygen reduction (Phase III) showed a more
408 independent metabolic regulation related to a phenotype. This suggested a more complex and diverse
409 regulation of intracellular processes over Phase III for the different phenotypes, contrary to the orderly

410 shift-down previously described (Cunningham and Spreadbury, 1998). This observation emphasises
411 the importance of integrated data from several levels of cellular regulation to guarantee sufficient data
412 for a more complex understanding of the biological processes as a whole.

413 In conclusion, all five *Mycobacterium* species can be considered as model organisms for Mtb in relation
414 to cell wall and MK9 synthesis over the cultures conditions tested. Whereas, most other metabolic
415 changes detected over the three culture conditions (e.g. poly-L-glutamate layer over Phase III) showed
416 a divide between fast- and slow-growing mycobacteria. This suggested that for metabolite profiling
417 study purposes *Mycobacterium* species phenotypically closer related to Mtb (e.g. *M. bovis* BCG and *M.*
418 *avium*) should be recommended as model organism. Given that a chloroform/methanol/water step,
419 lethal to mycobacteria, is used for the extraction of metabolites, the methodology is applicable to use
420 with ACDP3 pathogens such as virulent Mtb. The strong correlation between responses detected in the
421 present laboratory based study and published data, often acquired under conditions approaching *in*
422 *vivo* scenarios, adds support to the metabolomic approach as a means of obtaining conclusive datasets
423 for interpretation into exploitable networks. Thus, a metabolite profiling of at least one Mtb strain should
424 be done to further validate the presented conclusions and lead to a more precise consideration for the
425 choice of model species for metabolic modelling.
426
427

REFERENCES

Amon, J., Titgemeyer, F., and Burkovski, A. (2009). A genomic view on nitrogen metabolism and nitrogen control in mycobacteria. *J Mol Microbiol Biotechnol* **17**, 20-29.

Archuleta, R.J., Yvonne Hoppes, P., and Primm, T.P. (2005). Mycobacterium avium enters a state of metabolic dormancy in response to starvation. *Tuberculosis* **85**, 147-158.

Bacon, J., Alderwick, L.J., Allnutt, J.A., Gabasova, E., Watson, R., Hatch, K.A., Clark, S.O., Jeeves, R.E., Marriott, A., Rayner, E., Tolley, H., Pearson, G., Hall, G., Besra, G.S., Wernisch, L., Williams, A., and Marsh, P.D. (2014). Non-replicating Mycobacterium tuberculosis elicits a reduced infectivity profile with corresponding modifications to the cell wall and extracellular matrix. *PLoS One* **9**, e87329.

Barry, I.I.I.C.E. (2001). Mycobacterium smegmatis: an absurd model for tuberculosis? *Trends Microbiol* **9**, 473-474.

Betts, J.C., Lukey, P.T., Robb, L.C., McAdam, R.A., and Duncan, K. (2002). Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. *Mol Microbiol* **43**, 717-731.

Boshoff, H.I., and Lun, D.S. (2010). Systems biology approaches to understanding mycobacterial survival mechanisms. *Drug Discov Today Dis Mech* **7**, e75-e82.

Chao, M.C., and Rubin, E.J. (2010). Letting sleeping dos lie: does dormancy play a role in tuberculosis? *Annual review of microbiology* **64**, 293-311.

Cossu, A., Sechi, L.A., Zanetti, S., and Rosu, V. (2012). Gene expression profiling of Mycobacterium avium subsp. paratuberculosis in simulated multi-stress conditions and within THP-1 cells reveals a new kind of interactive intramacrophage behaviour. *BMC Microbiol* **12**, 87.

Crellin, P.K., Luo, C.-Y., and Morita, Y.S. (2013). Metabolism of Plasma Membrane Lipids in Mycobacteria and Corynebacteria. In *Lipid Metabolism*, Vol., p.^pp. 119 - 148,Edited by Baez, P.R.V.

Cunningham, A.F., and Spreadbury, C.L. (1998). Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog. *Journal of bacteriology* **180**, 801-808.

Dhiman, R.K., Mahapatra, S., Slayden, R.A., Boyne, M.E., Lenaerts, A., Hinshaw, J.C., Angala, S.K., Chatterjee, D., Biswas, K., Narayanasamy, P., Kurosu, M., and Crick, D.C. (2009). Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. *Mol Microbiol* **72**, 85-97.

Drapal, M., Perez-Fons, L., Wheeler, P.R., and Fraser, P.D. (2014). The application of metabolite profiling to Mycobacterium spp.: determination of metabolite changes associated with growth. *J Microbiol Methods* **106**, 23-32.

Eoh, H., and Rhee, K.Y. (2013). Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in Mycobacterium tuberculosis. *Proc Natl Acad Sci U S A* **110**, 6554-6559.

Gago, G., Diacovich, L., Arabolaza, A., Tsai, S.C., and Gramajo, H. (2011). Fatty acid biosynthesis in actinomycetes. *FEMS Microbiol Rev* **35**, 475-497.

Garton, N.J., Christensen, H., Minnikin, D.E., Adegbola, R.A., and Barer, M.R. (2002). Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum. *Microbiology* **148**, 2951-2958.

474 **Hampshire, T., Soneji, S., Bacon, J., James, B.W., Hinds, J., Laing, K., Stabler, R.A., Marsh, P.D., and**
475   **Butcher, P.D. (2004).** Stationary phase gene expression of Mycobacterium tuberculosis
476   following a progressive nutrient depletion: a model for persistent organisms? *Tuberculosis*
477   **84**, 228-238.
478 **Harrigan, G.G., and Goodacre, R. (2003).** Introduction. In *Metabolic profiling - Its Role in Biomarker*
479   *Discovery and Gene Function Analysis*, Vol., p.^pp. 1-9. Kluwer Academic Publishers,Edited
480   by Harrigan, G.G., and Goodacre, R. (ed.),^(eds.), United States of America.
481 **Harth, G., and Horwitz, M.A. (1999).** An inhibitor of exported Mycobacterium tuberculosis
482   glutamine synthetase selectively blocks the growth of pathogenic mycobacteria in axenic
483   culture and in human monocytes: extracellular proteins as potential novel drug targets. *J Exp*
484   *Med* **189**, 1425-1436.
485 **Jones, M.O., Perez-Fons, L., Robertson, F.P., Bramley, P.M., and Fraser, P.D. (2013).** Functional
486   characterization of long-chain prenyl diphosphate synthases from tomato. *Biochem J* **449**,
487   729-740.
488 **Kanehisa, M., Goto, S., Hattori, M., Aoki-Kinoshita, K.F., Itoh, M., Kawashima, S., Katayama, T.,**
489   **Araki, M., and Hirakawa, M. (2006).** From genomics to chemical genomics: new
490   developments in KEGG. *Nucleic Acids Res* **34**, D354-357.
491 **Lee, P.C., Salomon, C., Mijts, B., and Schmidt-Dannert, C. (2008).** Biosynthesis of ubiquinone
492   compounds with conjugated prenyl side chains. *Appl Environ Microbiol* **74**, 6908-6917.
493 **Low, K.L., Rao, P.S., Shui, G., Bendt, A.K., Pethe, K., Dick, T., and Wenk, M.R. (2009).** Triacylglycerol
494   utilization is required for regrowth of in vitro hypoxic nonreplicating Mycobacterium bovis
495   bacillus Calmette-Guerin. *Journal of bacteriology* **191**, 5037-5043.
496 **Mathew, R., Kruthiventi, A.K., Prasad, J.V., Kumar, S.P., Srinu, G., and Chatterji, D. (2010).**
497   Inhibition of mycobacterial growth by plumbagin derivatives. *Chem Biol Drug Des* **76**, 34-42.
498 **Mora, L., Bramley, P.M., and Fraser, P.D. (2013).** Development and optimisation of a label-free
499   quantitative proteomic procedure and its application in the assessment of genetically
500   modified tomato fruit. *Proteomics* **13**, 2016-2030.
501 **Nogueira, M., Mora, L., Enfissi, E.M., Bramley, P.M., and Fraser, P.D. (2013).** Subchromoplast
502   sequestration of carotenoids affects regulatory mechanisms in tomato lines expressing
503   different carotenoid gene combinations. *Plant Cell* **25**, 4560-4579.
504 **Rafidinarivo, E., Lanéelle, M.A., Montrozier, H., Valero-Guillén, P., Astola, J., Luquin, M., Promé,**
505   **J.C., and Daffé, M. (2009).** Trafficking pathways of mycolic acids: structures, origin,
506   mechanism of formation, and storage form of mycobacteric acids. *J Lipid Res* **50**, 477-490.
507 **Robertson, F.P., Koistinen, P.K., Gerrish, C., Halket, J.M., Patel, R.K., Fraser, P.D., and Bramley,**
508   **P.M. (2012).** Proteome changes in tomato lines transformed with phytoene synthase-1 in
509   the sense and antisense orientations. *J Exp Bot* **63**, 6035-6043.
510 **Russell, D.G., VanderVen, B.C., Lee, W., Abramovitch, R.B., Kim, M.J., Homolka, S., Niemann, S.,**
511   **and Rohde, K.H. (2010).** Mycobacterium tuberculosis wears what it eats. *Cell Host Microbe*
512   **8**, 68-76.
513 **Sassetti, C.M., Boyd, D.H., and Rubin, E.J. (2003).** Genes required for mycobacterial growth defined
514   by high density mutagenesis. *Mol Microbiol* **48**, 77-84.
515 **Sassetti, C.M., and Rubin, E.J. (2003).** Genetic requirements for mycobacterial survival during
516   infection. *Proc Natl Acad Sci U S A* **100**, 12989-12994.
517 **Selishcheva, A.A., Sorokoumova, G.M., and Nazarova, E.V. (2012).** Lipid Surrounding of
518   Mycobacteria: Lethal and Resuscitating Effects In *Understanding Tuberculosis - Deciphering*
519   *the Secret Life of the Bacilli*, Vol., p.^pp. 239-256. InTech,Edited by Cardona, P.-J.
520 **Shi, L., Sohaskey, C.D., Pfeiffer, C., Datta, P., Parks, M., McFadden, J., North, R.J., and Gennaro,**
521   **M.L. (2010).** Carbon flux rerouting during Mycobacterium tuberculosis growth arrest. *Mol*
522   *Microbiol* **78**, 1199-1215.

523 **Singhal, A., Arora, G., Sajid, A., Maji, A., Bhat, A., Virmani, R., Upadhyay, S., Nandicoori, V.K.,**
524   **Sengupta, S., and Singh, Y. (2013).** Regulation of homocysteine metabolism by
525   Mycobacterium tuberculosis S-adenosylhomocysteine hydrolase. *Sci Rep* **3**, 2264.
526 **Smeulders, M.J., Keer, J., Speight, R.A., and Williams, H.D. (1999).** Adaptation of Mycobacterium
527   smegmatis to stationary phase. *Journal of bacteriology* **181**, 270-283.
528 **Stehr, M., Elamin, A.A., and Singh, M. (2013).** Lipid inclusions in mycobacterial infections. In
529   Mahboub, B. (ed.), *Tuberculosis - Current Issues in Diagnosis and Management*. INTECH.
530 **Venkatesh, J., Kumar, P., Krishna, P.S., Manjunath, R., and Varshney, U. (2003).** Importance of
531   uracil DNA glycosylase in Pseudomonas aeruginosa and Mycobacterium smegmatis, G+C-rich
532   bacteria, in mutation prevention, tolerance to acidified nitrite, and endurance in mouse
533   macrophages. *The Journal of biological chemistry* **278**, 24350-24358.
534 **Walker, R.W., Barakat, H., and Hung, J.G. (1970).** The positional distribution of fatty acids in the
535   phospholipids and triglycerides of Mycobacterium smegmatis and M. bovis BCG. *Lipids* **5**,
536   684-691.
537 **Wang, R., Prince, J.T., and Marcotte, E.M. (2005).** Mass spectrometry of the M. smegmatis
538   proteome: protein expression levels correlate with function, operons, and codon bias.
539   *Genome Res* **15**, 1118-1126.
540 **Wayne, L.G., and Hayes, L.G. (1996).** An in vitro model for sequential study of shiftdown of
541   Mycobacterium tuberculosis through two stages of nonreplicating persistence. *Infect Immun*
542   **64**, 2062-2069.
543 **Wayne, L.G., and Sohaskey, C.D. (2001).** Nonreplicating persistence of mycobacterium tuberculosis.
544   *Annual review of microbiology* **55**, 139-163.
545 **Zeng, L., Shi, T., Zhao, Q., and Xie, J. (2013).** Mycobacterium sulfur metabolism and implications for
546   novel drug targets. *Cell Biochem Biophys* **65**, 77-83.
547
548

SUPPORTING INFORMATION

550 Supplementary File 1 – OD and cfu values of all growth conditions and mycobacteria

551 Supplementary File 2 - Average ratios and P-values of all growth conditions and mycobacteria

552

553 **FIGURE LEGENDS**

554 **Fig. 1.** Growth curves of *M. smegmatis* (a) and *M. bovis* BCG (b) under aerated and hypoxic cultivation.
555 These are representative of all the mycobacteria studied, though the actual OD values and sampling
556 points (diamonds, crosses and circles) vary for each species tested is (see methods). For Phase I
557 measurements were taken from lag to stationary phase. The induction time of elongated, aerated
558 (Phase II) and hypoxic (Phase III) cultivation is indicated by an arrow.

559 **Fig. 2.** Heat map of metabolite levels measured from lag phase over log and stationary phase. *M.*
560 *smegmatis, M. phlei, M. bovis* BCG, *M. avium* and *M. intracellulare* were grown under aerated
561 conditions and sampled at lag, log and stationary phase. The reference point for metabolite levels was
562 lag phase. Metabolites were grouped in polar (nucleotides, amino acids, organic acids and saccharides)
563 and non-polar (fatty acids, glycerol, -esters, -phosphates and isoprenoids) extracts. Changes are
564 indicated as increase (green), no change (grey), decrease (red) and not detected (white) shown in the
565 legend. Results were means of five replicates.

566 **Fig. 3.** Heat map of metabolite levels measured over Phase II. *M. smegmatis, M. phlei, M. bovis* BCG,
567 *M. avium* and *M. intracellulare* were grown under aerated conditions throughout and sampled from log
568 phase onwards over 28d. The reference point for metabolite levels was the first sampling point at log
569 phase. Metabolites were grouped in polar (nucleotides, amino acids, organic acids and saccharides)
570 and non-polar (fatty acids, glycerol, -esters, -phosphates and isoprenoids) extracts. Changes are
571 indicated as increase (green), no change (grey), decrease (red) and not detected (white) shown in the
572 legend. Results were means of five replicates.

573 **Fig. 4.** Heat map of metabolite levels measured over Phase III. *M. smegmatis, M. phlei, M. bovis* BCG,
574 *M. avium* and *M. intracellulare.* Those mycobacteria were grown under hypoxic conditions from log
575 phase onwards and sampled over this period until 28d. The reference point for metabolite levels was
576 the first sampling point at log phase. Metabolites were grouped in polar (nucleotides, amino acids,
577 organic acids and saccharides) and non-polar (fatty acids, glycerol, -esters, -phosphates and
578 isoprenoids) extracts. Changes are indicated as increase (green), no change (grey), decrease (red) and
579 not detected (white) shown in the legend. Results were means of five replicates.

580 **Fig. 5** Lipid **s**ecretion of *M. smegmatis* under hypoxic cultivation. (a) The secretion layer occurred
581 after three to four days of hypoxic cultivation of *M. smegmatis*. The translucent secretion layer (arrow)
582 was collected and analysed with MALDI for metabolite composition. (b) An average MALDI spectrum is
583 presented.

584 **Fig. 6.** Schematic representation of metabolic processes of mycobacteria over Phase I, II and III.
585 Mycobacterial cells were schematically displayed for Phase I, II and III. Arrows represented the

586 transition from Phase I to Phase II or III with depletion (cross) of oxygen (O_2) and/or nutrients.
587 Intracellular metabolic processes were indicated with black arrows and utilisation of compound classes
588 for the cell wall (grey circle) with grey arrows. The same changes of compound classes for all
589 mycobacteria tested were highlighted as up- and down- regulated (green and red, respectively).

590

591

592

593

594

595

596

597

598

599